BioCentury
ARTICLE | Financial News

Gene therapy company Tocagen proposes $86.3M IPO

March 10, 2017 11:12 PM UTC

Tocagen Inc. (San Diego, Calif.) proposed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Leerink, Evercore and Stifel.

The gene therapy company expects to report top-line results in 1H18 from the Phase II portion of a Phase II/III study of lead candidate Toca 511/Toca FC to treat recurrent high-grade glioma. The candidate has Fast Track and breakthrough therapy designations in the indication. ...

BCIQ Company Profiles

Tocagen Inc.